Opinion ID: 2814134
Heading Depth: 2
Heading Rank: 4

Heading: daiichi’s patents

Text: Daiichi is a pharmaceutical company that owns three patents that it claims have been affected by the PTO’s pre-Wyeth interpretation. These three patents, U.S. Patent Nos. 7,342,014 (“’014 patent”), 7,365,205 (“’205 patent”), and 7,567,135 (“’135 patent”), cover compounds that are useful for treating tissue death due to lack of oxygen, blood clots, and other ailments. The ’014 and ’205 patents issued before August 5, 2009 and, thus, did not qualify for the Optional Interim Procedure. 3 According to Daiichi, in the PTO’s patent term adjustment calculations for each of Daiichi’s patents in this case, the agency chose to restore days for either the A or B Delay, but not both. Daiichi claims that the term of each of its patents was shortened by at least 321 days under the pre-Wyeth calculation method. 3 As discussed below, the ’135 patent issued after August 5, 2009. Daiichi invoked the Optional Interim Procedure for the ’135 patent. 6 DAIICHI SANKYO COMPANY v. LEE